Kyiv, Vyshgorodska str., 67 (entrance off Kobzarska str.), 4th floor, room 105

Sarcopenia Muscles and age


The ‘sarcopenia’ (from Gr. Sarx- body, flesh, penia – decrease) term was introduced by Rozenberg I. to describe the age-related skeletal muscle loss in 1989.

In 1998, Baumgartner R. Defined sarcopenia as a syndrome associated with an increased fall risk and reduced physical strength (Rosenberg I., 1997; Rosenberg I., 1998; Morley J. E. et al., 2001).

According to the American Center for Disease Control (CDC), sarcopenia ranks among five principal risk factors for morbidity and mortality of people over 65 years (Rolland Y. et al., 2009; Burton L.A., Sumukadas D., 2010; Cruz-Jentoft A.J. et al., 2010).

Sarcopenia is associated with an increased fall risk, deteriorated life quality, moving disorders, reduced lifespan and increased mortality (Morley J.E. et al., 2009; Cruz-Jentoft A. et al., 2010; Di Monaco M. et al. 2011; Landi F. et al., 2012; Arango-Lopera V.E. et al., 2013; Landi F. et al., 2013).

In 2009, the European Union Geriatric Medicine Society (EUGMS) created a working group, the European Working Group on Sarcopenia in Older People (EWGSOP), for studying sarcopenia in order to develop definitions and diagnostic criteria for the clinical trials and clinical practice (Cruz-Jentoft A.J. et al., 2010). Other European societies, such as the European Society of Clinical Nutrition and Metabolism (ESPEN), the International Academy of Nutrition and Aging (IANA), the International Association of Gerontology, Geriatrics - European Region (IAGG-ER), were later invited to sit on the Working Group. As a result, five societies (EWGSOP, EUGMS, ESPEN, IAGG-ER, IANA) co-authored the first Consensus on Sarcopenia Diagnostics (Cruz-Jentoft A. J. et al., 2010; Volpato S. et al., 2014).

SARCOPENIA – a syndrome characterized by a progressive generalized body mass and skeletal muscle strength which is associated with such complications as moving disorders, reduced life quality and may lead to mortality (EWGSOP, 2010).

Sarcopenia’s prevalence varies greatly (5 – 70 %) depending on age, sex and ethnicity (Di Monaco M., 2011; Cruz-Jentoft A. J., 2010; Buehring B., Binkley N., 2013).


In the recent years, a new term, sarco-osteoporosis, comes up signifying a combination of sarcopenia and osteoporosis which leads to a significantly increased fall risk, fragility fractures, morbidity and mortality. Its invention is prompted by the fact that in multiple studies more than 50 % of elderly and older patients had both sarcopenia and osteoporosis (Burton L. A., Sumukadas D., 2010; Di Monaco M. et al., 2011; Verschueren S. et al., 2013).

Sarcopenia’s urgency and its medicosocial consequences have a global reach. In Ukraine, the first sarcopenia studies were performed under Prof. V.V. Povoroznyuk’s supervision.

monograph Sarcopenia

In October 2016, a group of scientists: V.V. Povoroznyuk (Ukraine), N. Bimkley (USA), N.I. Dzerovych (Ukraine), R.V. Povoroznyuk (Ukraine), supported by the Ukrainian Scientific-Medical Center of Osteoporosis Problems, published a monograph ‘Sarcopenia’ (See here). (LINK MONOGRAPHY)

You’re invited to the Ukrainian Scientific-Medical Center of Osteoporosis Problems to be diagnosed for sarcopenia and to get answers on prophylaxis and treatment.

Go to the center